Dydrogesterone versus micronized vaginal progesterone as luteal phase support after fresh embryo transfer in IVF

被引：2

作者：

Tataru, C. ^{[1
]}

Dessapt, A. -l. ^{[1
]}

Pietin-Vialle, C. ^{[1
]}

Pasquier, M. ^{[1
]}

Bry-Gauillard, H. ^{[1
]}

Massin, N. ^{[1
]}

机构：

[1] Univ Paris 12, Ctr Hosp Intercommunal Creteil, Serv Gynecol Obstet & Med Reprod, 40 Ave Verdun, F-94000 Creteil, Val De Marne, France

来源：

GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE | 2022年 / 50卷 / 06期

关键词：

Dydrogesterone; Progesterone; Luteal phase support; IVF; Real-world study; ASSISTED REPRODUCTIVE TECHNOLOGY; ORAL DYDROGESTERONE; SAFETY;

D O I：

10.1016/j.gofs.2021.12.014

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

A B S T R A C T Objectives. - The objective of the study was to compare the live birth rate and miscarriage rate after fresh embryo transfer (Fresh ET) when patients are treated either with oral dydrogesterone or micronized vaginal progesterone (MVP) as luteal phase support (LPS). The vaginal route is still preferred, despite the discomfort for the patients and recent RCTs showing similar results for dydrogesterone and MVP. Methods. - All 556 consecutive Fresh ET after autologous IVF procedure, from December 2011 to March 2013 in one centre in France were included. Patients were treated either with dydrogesterone 10 mg every 12 hours (n = 267) or MVP 200 mg every 12 hours (n = 289), the physician's arbitrary choice on the day of the oocyte aspiration procedure.

引用

收藏

页码：455 / 461

页数：7

相关论文

共 30 条

[1] Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks [J].

Aboulghar, Mohamed A. ;

Amin, Yahia M. ;

Al-Inany, Hesham G. ;

Aboulghar, Mona M. ;

Mourad, Latouna M. ;

Serour, Gamal I. ;

Mansour, Ragaa T. .

HUMAN REPRODUCTION, 2008, 23 (04) :857-862

[2]

[Anonymous], 2008, PRACTICE COMMITTEE A

[3]

[Anonymous], 2007, ANN REPORT

[4] Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: Results of a randomised study [J].

Chakravarty, BN ;

Shirazee, HH ;

Dam, P ;

Goswami, SK ;

Chatterjee, R ;

Ghosh, S .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2005, 97 (05) :416-420

[5] Timing luteal support in assisted reproductive technology: a systematic review [J].

Connell, Matthew T. ;

Szatkowski, Jennifer M. ;

Terry, Nancy ;

DeCherney, Alan H. ;

Propst, Anthony M. ;

Hill, Micah J. .

FERTILITY AND STERILITY, 2015, 103 (04) :939-U112

[6] EFFECTS OF LUTECTOMY AND PROGESTERONE REPLACEMENT THERAPY IN EARLY PREGNANT PATIENTS [J].

CSAPO, AI ;

PULKKINEN, MO ;

WIEST, WG .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1973, 115 (06) :759-265

[7]

EDWARDS RG, 1980, BRIT J OBSTET GYNAEC, V87, P737, DOI 10.1111/j.1471-0528.1980.tb04610.x

[8] Effect of oral administration of dydrogestrone versus vaginal administration of natural micronized progesterone on the secretory transformation of endometrium and luteal endocrine profile in patients with premature ovarian failure: a proof of concept [J].

Fatemi, H. M. ;

Bourgain, C. ;

Donoso, P. ;

Blockeel, C. ;

Papanikolaou, E. G. ;

Popovic-Todorovic, B. ;

Devroey, P. .

HUMAN REPRODUCTION, 2007, 22 (05) :1260-1263

[9] Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study [J].

Ganesh, Ashalatha ;

Chakravorty, Nishant ;

Mukherjee, Rashmi ;

Goswami, Sourendrakanta ;

Chaudhury, Koel ;

Chakravarty, Baidyanath .

FERTILITY AND STERILITY, 2011, 95 (06) :1961-1965

[10] Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis [J].

Griesinger, Georg ;

Blockeel, Christophe ;

Kahler, Elke ;

Pexman-Fieth, Claire ;

Olofsson, Jan, I ;

Driessen, Stefan ;

Tournaye, Herman .

PLOS ONE, 2020, 15 (11)